Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
95 Obesity Trials near Austin, TX
Power is an online platform that helps thousands of Obesity patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerOrforglipron for Obesity
Shavano Park, Texas
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
1200 Participants Needed
Orforglipron for Type 2 Diabetes and Obesity
Shavano Park, Texas
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO.
Participation in the study will last about 18 months.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Type 1 Diabetes, Heart Failure, Others
Must Not Be Taking:Weight Loss Drugs
600 Participants Needed
Orforglipron for Obesity
Shavano Park, Texas
The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792).
Participation in the study will last about 18 months.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Diabetes, Unstable Weight, Heart Failure, Others
Must Not Be Taking:Weight Loss Medications
600 Participants Needed
Tirzepatide for Weight Loss Maintenance in Obesity
Shavano Park, Texas
This trial is testing tirzepatide, a medication that helps people lose weight, to see if it can also help them keep the weight off. The study involves people who have already lost weight and need help maintaining it. Tirzepatide works by making people feel full and reducing their appetite. Tirzepatide has been effective in helping people lose weight and manage blood sugar levels.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Diabetes, Pancreatitis, Cardiovascular, Depression, Others
400 Participants Needed
Macupatide + Eloralintide for Obesity
Shavano Park, Texas
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Type 1 Diabetes, Cardiovascular Conditions, Malignancy, Others
Must Be Taking:Metformin, SGLT2 Inhibitors
200 Participants Needed
Semaglutide + Low-Dose Insulin Glargine for Type 2 Diabetes
Shavano Park, Texas
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home visit. Participants will be asked to wear a sensor that measures their blood sugar all the time in 2 periods of 10 days during the study.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Not Listed
568 Participants Needed
Retatrutide for Obesity
San Antonio, Texas
This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Diabetes, Thyroid Cancer, Heart Failure, Others
Must Not Be Taking:Weight Loss Drugs
643 Participants Needed
Retatrutide for Obesity
San Antonio, Texas
This trial is testing a weekly medication called retatrutide. It aims to help people who are overweight or obese and have knee osteoarthritis. The study will last over a year to see if the medication is safe and effective.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Steroid Injections, Joint Disease, Diabetes, Others
Must Not Be Taking:Weight Loss Drugs
405 Participants Needed
Orforglipron for Obesity
San Antonio, Texas
This trial will test a daily pill called orforglipron to see if it helps people who are overweight or obese and have type 2 diabetes lose weight. The study will last over a year and involve multiple visits.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Type 1 Diabetes, Pancreatitis, Others
Must Be Taking:Oral Antihyperglycemics
1500 Participants Needed
Semaglutide for Obesity
San Antonio, Texas
The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All participants will get semaglutide treatment for a minimum of 3 years.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:12 - 15
Key Eligibility Criteria
Disqualifiers:Prepubertal, Obesity Surgery, Diabetes, Others
Must Be Taking:Semaglutide
500 Participants Needed
CX11 for Obesity
San Antonio, Texas
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study:
* To evaluate the efficacy of different dose levels of CX11 tablets in body weight reduction as compared to placebo.
* To compare the changes of effects in weight and weight-related indicators at the visit time points.
* To evaluate the tolerability and safety of different doses of CX11 tablets in overweight/obese participants.
* To assess the pharmacokinetics (PK) of different doses of CX11 tablets in overweight/obese participants.
Overweight/obese participants who are successfully screened will be randomized in a 1:1:1:1:1 ratio to different doses of CX11 tablets or placebo. All participants will enter a 2-week follow-up period after 36 weeks of treatment for safety observation.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Diabetes, Heart Problems, Cancer, Others
Must Not Be Taking:GLP-1 Receptor Agonists
250 Participants Needed
RGT001-075 for Obesity
San Antonio, Texas
This is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of RGT001-075 in adults who are obese (BMI ≥30 kg/m²) or who are overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. RGT001-075 or matching placebo will be administered once daily.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Diabetes, Pancreatitis, Gallbladder Disease, Others
Must Not Be Taking:GLP-1 Analogs
236 Participants Needed
TERN-601 for Obesity
San Antonio, Texas
This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Diabetes, Endocrinologic Disorders, Others
150 Participants Needed
AZD6234 for Type 2 Diabetes and Obesity
San Antonio, Texas
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Bariatric Surgery, Hepatobiliary Disease, Others
Must Be Taking:GLP-1 RA
64 Participants Needed
Petrelintide for Obesity
San Antonio, Texas
The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Diabetes, Major Depression, Cardiovascular, Others
Must Not Be Taking:Glucose Lowering Agents, Weight Loss Meds
493 Participants Needed
Apitegromab for Obesity
San Antonio, Texas
A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 agonist therapy in subjects with overweight or obesity
Stay on current meds
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Cardiovascular, Neurovascular, Pulmonary, Diabetes, Others
Must Be Taking:GLP-1 Agonists
100 Participants Needed
CagriSema for Chronic Kidney Disease and Type 2 Diabetes in Obesity
San Antonio, Texas
This trial is testing a new medicine called CagriSema to see if it can reduce kidney damage in people with chronic kidney disease, type 2 diabetes, and who are overweight or obese. The study will compare CagriSema to two other medicines.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Hereditary Kidney Diseases, Dialysis, Others
Must Be Taking:Ace Inhibitors, Arbs
618 Participants Needed
Treatments for Prediabetes and Obesity
San Antonio, Texas
The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight. The investigators also want to reduce participants risk of heart problems. The study team will look at how these treatments affect metabolism and other body functions to help find new ways to treat diabetes and obesity in the future.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Type 2 Diabetes, Major Oncologic, Others
Must Not Be Taking:Selected Therapies
64 Participants Needed
Cagrilintide for Obesity
San Antonio, Texas
This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human body does to the study medicine. Participants will either get the new study medicine NNC0174-1213, a study medicine called "cagrilintide" or a placebo (a "dummy medicine" similar to the new study medicine and study medicine but without active ingredients). Which treatment participants will get is decided by chance. The new study medicine and the study medicine are potential new medicines which cannot be prescribed by doctors. This study will last for about a year in total.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:Male
Key Eligibility Criteria
Disqualifiers:Liver Impairment, Renal Impairment, Diabetes, Others
Must Not Be Taking:Amylin, Calcitonin Receptor Agonists
177 Participants Needed
NNC0519-0130 for Obesity
San Antonio, Texas
This study will look into a new study medicine called NNC0519-0130 to improve the treatment option for people living with excess body weight or type 2 diabetes or both. The purpose of this study is to compare the amount of NNC0519-0130 in the blood of participants who have excess body weight. The study comprises two parts and the participants will receive both preparations NNC0519-0130 B and NNC0519-0130 C, which treatment the participants get is decided by chance. The study will last for about 24 weeks.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 64
Key Eligibility Criteria
Disqualifiers:Diabetes, Respiratory, Cardiovascular, Others
Must Not Be Taking:Prescription Drugs
46 Participants Needed
Why Other Patients Applied
"I have a heart condition, and my fat is all in my chest, surrounding my heart. It's hard for me to exercise because my legs are thin and the upper body weight is too much — putting strain on my leg joints. It’s a vicious cycle. I am also post-menopausal, which adds additional weight loss difficulty. I also have stress with being a full time caregiver for my mom. I'm interested in trying a clinical trial."
DK
Obesity PatientAge: 56
"I am applying for my daughter. She turns 12 this year and is overweight. She's 5'4" and 176 pounds. Would be great to enroll her in a clinical trial to see if this form of care could work for her. Realize that there's no guarantee, but I support her and we'd like to give it a try."
MW
Parent of PatientAge: 46
"I need to lose weight because it's affecting my knees. I've already had a knee replacement and the second one is happening on the left knee in a few months. I've participated in a study in the past for a skin-related issue, and had a good experience. That's why I'm interested in joining a study for wieght loss."
KI
Obesity PatientAge: 69
"I have tried to lose weight, but as I get older, it becomes harder and harder. I have lost weight in the past through diet and exercise, but it has been more difficult to accomplish as I age."
JP
Obesity PatientAge: 44
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
GS-4571 for Type 2 Diabetes
San Antonio, Texas
The goal of this clinical study is to learn more about the study drug, GS-4571, and how safe it is in 3 groups, i) Healthy participants, ii) Healthy non-diabetic obese participants, and iii) Non-obese participants with Type 2 Diabetes Mellitus (T2DM).
The primary objectives of this study are:
* To characterize the pharmacokinetics (PK) of GS-4571 following single and multiple ascending oral doses of GS-4571.
* To evaluate the effect of concomitant food intake and (if conducted) a representative acid-reducing agent (proton pump inhibitor (PPI), omeprazole) on the PK of GS-4571.
* To evaluate the safety and tolerability of single and multiple ascending oral doses of GS-4571.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55
Key Eligibility Criteria
Disqualifiers:Serious Illness, Pancreatitis, Cardiac Disease, Others
Must Be Taking:Metformin
134 Participants Needed
LY3971297 for Obesity
San Antonio, Texas
This trial is testing a new drug called LY3971297, which is given as an injection under the skin. The study includes both healthy people and obese people with high blood pressure. Researchers will take blood samples to see how much of the drug enters the bloodstream and how long it stays in the body.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Cardiovascular, Renal, Psychiatric, Others
Must Be Taking:Antihypertensives, ACE Inhibitors
225 Participants Needed
Diet and Exercise for Post-COVID Syndrome
San Antonio, Texas
The research in this VA Merit will examine the effects of obesity and Post-COVID Conditions (PCC) on physical functioning, health-related quality of life, and adipose tissue inflammatory and cellular senescence profiles in older Veterans. Further, it will evaluate whether a weight loss intervention, including dietary modification and exercise, in obese Veterans with and without PCC will reduce systemic and adipose tissue inflammation and senescence and promote PCC recovery.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:55 - 80
Key Eligibility Criteria
Disqualifiers:Neurologic, Autoimmune, Uncontrolled Diabetes, Others
Must Not Be Taking:Insulin, Anti-coagulants
150 Participants Needed
Retatrutide for Obesity
San Antonio, Texas
The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.
Participation in the study will last about 65 weeks and may include about 18 visits.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Diabetes, Thyroid Cancer, Pancreatitis, Others
Must Not Be Taking:Weight Loss Drugs
250 Participants Needed
GSBR-1290 for Obesity
San Antonio, Texas
Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet and exercise, over a 44-week period.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Diabetes, Recent Weight Change, Others
Must Not Be Taking:Weight Loss Medications
82 Participants Needed
LY4086940 for Obesity
San Antonio, Texas
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body.
Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 9 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Acute Cardiovascular, Liver Disease, Pancreatitis, Others
Must Not Be Taking:Weight Loss Drugs
186 Participants Needed
Orforglipron for Obesity
San Antonio, Texas
The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Diabetes, Unstable Weight, Hepatitis, Others
Must Not Be Taking:Weight Loss Medications
120 Participants Needed
NNC0638-0355 for Obesity
San Antonio, Texas
The study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in your body, and what your body does to the study medicine. Participants will either get the study medicine or placebo (a "dummy medicine" similar to the study medicine but without active ingredients) given as an injection under your skin. Which treatment the participants get is decided by chance. The study medicine is a potential new medicine which cannot be prescribed by doctors.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 55
Key Eligibility Criteria
Disqualifiers:Diabetes, Vitamin D Deficiency, Others
88 Participants Needed
Intermittent Fasting for Obesity
San Antonio, Texas
This trial is testing intermittent fasting as a way to help overweight and obese Veterans keep weight off after losing it. Intermittent fasting involves eating only during certain times and not eating at other times. The study will also look at how muscle enzymes that burn fat might help with long-term weight management. Intermittent fasting is a popular weight management intervention that has been widely applied to the treatment of overweight and obesity in adults.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:50 - 75
Key Eligibility Criteria
Disqualifiers:Diabetes, Autoimmune, Psychiatric, Others
Must Not Be Taking:Insulin, Anti-coagulants
175 Participants Needed
Mirikizumab + Tirzepatide for Ulcerative Colitis
San Antonio, Texas
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight.
Participation in this study will last up to 61 weeks, including 52 weeks of treatment.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Crohn's Disease, Type 1 Diabetes, Others
350 Participants Needed
Know someone looking for new options?
Spread the word